We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Glycan-Attaching Enzyme Defines Colon Cancer

By LabMedica International staff writers
Posted on 08 Feb 2018
Print article
Image: The LSM 710 confocal microscope (Photo courtesy of Carl Zeiss).
Image: The LSM 710 confocal microscope (Photo courtesy of Carl Zeiss).
An enzyme that is absent in healthy colon tissue but abundant in colon cancer cells and this enzyme appears to drive the conversion of normal colon tissue into cancer by attaching sugar molecules, or glycans, to certain proteins in the cell.

A group of 20 enzymes have been studied that initiate the first step in a particular kind of glycan modification, called N-acetylgalactosamine (GalNAc)-type O-glycosylation, found on diverse proteins. These enzymes, called GalNAc transferases (GalNAc -Ts) are variously found in different amounts in different tissues, but their functions are poorly understood.

Biochemists at the University of Copenhagen (Denmark) obtained tissue microarrays from frozen tissue samples were from colorectal adenocarcinoma patients. Healthy control samples were evaluated from frozen multiple organ normal tissue array. The sections were fixed in cold 10% buffered neutral formalin for 15 minutes or in cold acetone for 10 minutes. Immunohistochemistry was performed and processed and fluorescence micrographs were obtained on a Leica wide-field fluorescence microscope or a LSM710 confocal microscope.

The team used the EASY-nLC 1000 UHPLC interfaced via nanoSpray Flex ion source to an LTQ-Orbitrap Velos Pro mass spectrometer to categorize the proteins that GalNAc-T6 acted on cancer cells. The team used CRISPR/Cas engineering of a colon cancer cell line with and without GalNAc-T6 to understand which proteins the enzyme helped attach sugars to, and what effect this had on the cells. They found that one of the GalNAc-Ts, called GalNAc-T6, was absent in healthy colon tissue but abundant in colon cancer cells. Understanding the role that sugar-modified (glycosylated) proteins play in healthy and cancerous cells is an emerging area of cancer biology that may lead to new therapies.

Hans H. Wandall, PhD, a professor and lead investigator, said, “When we look at the 3D growth of a cancer cell line that has GalNAc-T6, it can form tubular structures with formation of something that looks like colon cancer tissue. When we take out GalNAc-T6, then suddenly the tissue formation changes to look more like the crypt structures that you would find in a healthy colon.” The study was published on January 26, 2018, in the Journal of Biological Chemistry.

Related Links:
University of Copenhagen

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.